Dr. Bachier on the Toxicity Profile of Liso-Cel

February 21, 2020
Carlos R. Bachier, MD

Carlos R. Bachier, MD, discusses the toxicity profile of lisocabtagene maraleucel that has been observed in 3 ongoing clinical trials in relapsed/refractory large B-cell non-Hodgkin lymphoma.

Carlos R. Bachier, MD, director, blood and marrow transplant research, Sarah Cannon Research Institute, discusses the toxicity profile of lisocabtagene maraleucel (liso-cel) that has been observed in 3 ongoing clinical trials in relapsed/refractory large B-cell non-Hodgkin lymphoma.

The adverse events (AEs) of liso-cel have been similar to that of other chimeric antigen receptor (CAR) T-cell products. With CAR T cells, there is potential for cytokine release syndrome (CRS), as well as neurological toxicities like confusion or seizures. These are known AEs of CAR T cells that are of concern with this therapy.

With liso-cel, the incidence rates, as well as severity, of neurological events and CRS appears lower compared with other CAR T-cell therapies, Bachier says.


x